Astellas ends ASP5502 Sjögren’s trial as Novartis’ ianalumab gains FDA breakthrough tag
Apr 22, 2026
Astellas terminated its phase 1 ASP5502 study in Sjögren’s syndrome as Novartis said the FDA granted breakthrough therapy designation to ianalumab. Novartis plans global regulatory submissions from early 2026 after positive phase III data.